Este site está a implementar funcionalidades principais e ainda não está pronto para utilização por pacientes.
Emergent BioSolutions Inc. is an American specialty pharmaceutical company founded in 1998, focused on emergency preparedness and travel vaccines. Manufacturer of BioThrax (anthrax), ACAM2000 (smallpox), and Vivotif (oral typhoid live attenuated vaccine Ty21a) — the most convenient typhoid vaccine for travelers, requiring no injections. Also produces BAYRAB (rabies immunoglobulin) for post-exposure prophylaxis.
Emergent BioSolutions was incorporated in 1998 and focuses on medical countermeasures (MCMs) for biological, chemical, radiological, and nuclear threats, as well as emerging infectious disease vaccines. Its crown jewel for travel medicine is Vivotif (Ty21a) — an oral typhoid vaccine taken as 4 capsules over 7 days, providing protection for 5+ years. Typhoid remains a significant risk for travelers to South Asia, Sub-Saharan Africa, Southeast Asia, and Latin America. Emergent also supplies BAYRAB and HyperRAB (rabies immunoglobulins) for post-exposure prophylaxis, critical for travelers bitten by potentially rabid animals.
Nenhum item FAQ disponível.